albuterol has been researched along with Recrudescence in 39 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the clinical efficacy and side effects of terbutaline and salbutamol administered by metered dose inhaler and holding chamber in the mild to moderate acute exacerbations of asthma in children." | 9.11 | Comparison of terbutaline and salbutamol inhalation in children with mild or moderate acute exacerbation of asthma. ( Chandra, P; Kabra, SK; Lodha, R; Paliwal, L, 2004) |
| "To determine the onset, magnitude, and duration of bronchodilation after administration of aerosolized salmeterol xinafoate in horses with recurrent airway obstruction." | 9.09 | Efficacy of salmeterol xinafoate in horses with recurrent airway obstruction. ( Henrikson, SL; Rush, BR, 2001) |
| "To determine the dose of aerosolized albuterol sulfate required to cause bronchodilation in horses with recurrent airway obstruction (RAO) and duration of this effect." | 7.70 | Aerosolized albuterol sulfate used as a bronchodilator in horses with recurrent airway obstruction. ( Berney, C; Derksen, FJ; Hakala, JE; Matson, CJ; Olszewski, MA; Robinson, NE; Ruth, DT, 1999) |
| "To determine whether pulmonary distribution of aerosolized technetium Tc 99m pentetate is improved after inhalation of a single dose of albuterol sulfate in horses susceptible to recurrent airway obstruction (heaves)." | 7.70 | Pulmonary distribution of aerosolized technetium Tc 99m pentetate after administration of a single dose of aerosolized albuterol sulfate in horses with recurrent airway obstruction. ( Davis, EG; Hakala, JE; Hoskinson, JJ; Matson, CJ; Rush, BR, 1999) |
| "A retrospective, case-controlled analysis comparing patients admitted to a medical intensive care unit with severe exacerbations of asthma who received continuously nebulized albuterol (CNA) versus intermittent albuterol (INA) treatments is reported." | 7.69 | Continuously nebulized albuterol in severe exacerbations of asthma in adults: a case-controlled study. ( Baker, EK; Marinac, JS; Salzman, GA; Willsie, SK, 1997) |
| "Subjects with acute exacerbation of asthma (FEV1 <50% predicted following 30 min of standardized treatment: 5 mg nebulized albuterol; 0." | 5.19 | Repeated dyspnea score and percent FEV1 are modest predictors of hospitalization/relapse in patients with acute asthma exacerbation. ( Ferguson, I; House, SL; Johnson, K; Lewis, LM; Liu, J; Matsuda, K; Schneider, JE, 2014) |
| "Our objective was to evaluate the efficacy and safety of two doses of fluticasone propionate (FP) in young children with recurrent wheezing and risk factors for asthma." | 5.11 | Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing. ( Bergadá, I; Colom, AJ; Kofman, CD; Maffey, AF; Teper, AM; Vidaurreta, SM, 2004) |
| "To compare the clinical efficacy and side effects of terbutaline and salbutamol administered by metered dose inhaler and holding chamber in the mild to moderate acute exacerbations of asthma in children." | 5.11 | Comparison of terbutaline and salbutamol inhalation in children with mild or moderate acute exacerbation of asthma. ( Chandra, P; Kabra, SK; Lodha, R; Paliwal, L, 2004) |
| "To determine the onset, magnitude, and duration of bronchodilation after administration of aerosolized salmeterol xinafoate in horses with recurrent airway obstruction." | 5.09 | Efficacy of salmeterol xinafoate in horses with recurrent airway obstruction. ( Henrikson, SL; Rush, BR, 2001) |
| " Both studies were continued for a further 9 months during which time exacerbation rates, lung function at the clinic and adverse events were monitored." | 3.78 | Efficacy and safety of salmeterol in childhood asthma. ( Boner, AL; Ebbutt, A; Jenkins, MM; Lenney, W; Pedersen, S, 1995) |
| "We measured the incremental cost-effectiveness from the perspective of the hospital, by creating a model using outcome characteristics from a Cochrane systematic review comparing the efficacy of using MDIs versus nebulizers for the delivery of albuterol to children presenting to the ED with asthma." | 3.77 | Cost-effectiveness of metered-dose inhalers for asthma exacerbations in the pediatric emergency department. ( Doan, Q; Johnson, D; Shefrin, A, 2011) |
| "We present a 19-month-old boy with a history of asthma who presented to the pediatric emergency department with noisy breathing and tachypnea partially responsive to albuterol." | 3.76 | A 19-month-old boy with recurrent respiratory distress. ( Cross, KP; Herr, SM; Randell, KA, 2010) |
| "To determine the dose of aerosolized albuterol sulfate required to cause bronchodilation in horses with recurrent airway obstruction (RAO) and duration of this effect." | 3.70 | Aerosolized albuterol sulfate used as a bronchodilator in horses with recurrent airway obstruction. ( Berney, C; Derksen, FJ; Hakala, JE; Matson, CJ; Olszewski, MA; Robinson, NE; Ruth, DT, 1999) |
| "To determine whether pulmonary distribution of aerosolized technetium Tc 99m pentetate is improved after inhalation of a single dose of albuterol sulfate in horses susceptible to recurrent airway obstruction (heaves)." | 3.70 | Pulmonary distribution of aerosolized technetium Tc 99m pentetate after administration of a single dose of aerosolized albuterol sulfate in horses with recurrent airway obstruction. ( Davis, EG; Hakala, JE; Hoskinson, JJ; Matson, CJ; Rush, BR, 1999) |
| "A retrospective, case-controlled analysis comparing patients admitted to a medical intensive care unit with severe exacerbations of asthma who received continuously nebulized albuterol (CNA) versus intermittent albuterol (INA) treatments is reported." | 3.69 | Continuously nebulized albuterol in severe exacerbations of asthma in adults: a case-controlled study. ( Baker, EK; Marinac, JS; Salzman, GA; Willsie, SK, 1997) |
| "ICS discontinuation after 30 months in COPD can worsen lung function decline, AHR, and QOL during 5-year follow-up." | 2.80 | Relapse in FEV1 Decline After Steroid Withdrawal in COPD. ( Hiemstra, PS; Kerstjens, HAM; Klooster, K; Kunz, LIZ; Lapperre, TS; Postma, DS; Snoeck-Stroband, JB; Sont, JK; Sterk, PJ; Vonk, JM, 2015) |
| "Prevention and treatment of COPD exacerbations are recognized as key goals in disease management." | 2.74 | Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. ( Anzueto, A; Chinsky, K; Crater, G; Emmett, A; Feldman, G; Ferguson, GT; Kalberg, C; Knobil, K; O'Dell, D; Seibert, A, 2009) |
| "Albuterol was administered through the spacer device (50 microg/kg) or through the nebulizer (150 microg/kg) and repeated 3 times at 20-minute intervals." | 2.69 | High-dose albuterol by metered-dose inhaler plus a spacer device versus nebulization in preschool children with recurrent wheezing: A double-blind, randomized equivalence trial. ( Chapuis, FR; Chatelain, PG; David, L; Dutau, G; Floret, D; Ploin, D; Robert, J; Stamm, D, 2000) |
"Treatment of COPD with fluticasone propionate/salmeterol 500/50 microg appears to be cost-effective (| 1.35 | Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. ( Chambers, MG; Dalal, AA; Earnshaw, SR; Jhingran, P; Mapel, DW; Stanford, R; Wilson, MR, 2009) | |
| "Chronic obstructive pulmonary disease (COPD) exacerbations are associated with increased airway and systemic inflammation, though relationships between exacerbation recovery, recurrent exacerbation and inflammation have not been previously reported." | 1.34 | Inflammatory changes, recovery and recurrence at COPD exacerbation. ( Donaldson, GC; Hurst, JR; Müllerova, H; Perera, WR; Sapsford, RJ; Wedzicha, JA; Wilkinson, TM, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (7.69) | 18.7374 |
| 1990's | 12 (30.77) | 18.2507 |
| 2000's | 13 (33.33) | 29.6817 |
| 2010's | 11 (28.21) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aliaga, CA | 1 |
| Arizon, LF | 1 |
| Bermúdez, RM | 1 |
| Castán, JAB | 1 |
| Santandreu, AV | 1 |
| Cetin, N | 1 |
| Yildiz, B | 1 |
| Kural, N | 1 |
| Schneider, JE | 1 |
| Lewis, LM | 1 |
| Ferguson, I | 1 |
| House, SL | 1 |
| Liu, J | 1 |
| Matsuda, K | 1 |
| Johnson, K | 1 |
| Kunz, LIZ | 1 |
| Postma, DS | 1 |
| Klooster, K | 1 |
| Lapperre, TS | 1 |
| Vonk, JM | 1 |
| Sont, JK | 1 |
| Kerstjens, HAM | 1 |
| Snoeck-Stroband, JB | 1 |
| Hiemstra, PS | 1 |
| Sterk, PJ | 1 |
| Migliorini, F | 1 |
| Porcaro, AB | 1 |
| Baldassarre, R | 1 |
| Artibani, W | 1 |
| Czövek, D | 1 |
| Shackleton, C | 1 |
| Hantos, Z | 1 |
| Taylor, K | 1 |
| Kumar, A | 1 |
| Chacko, A | 1 |
| Ware, RS | 1 |
| Makan, G | 1 |
| Radics, B | 1 |
| Gingl, Z | 1 |
| Sly, PD | 1 |
| Fitzpatrick, AM | 1 |
| Jackson, DJ | 1 |
| Mauger, DT | 1 |
| Boehmer, SJ | 1 |
| Phipatanakul, W | 1 |
| Sheehan, WJ | 1 |
| Moy, JN | 1 |
| Paul, IM | 1 |
| Bacharier, LB | 1 |
| Cabana, MD | 1 |
| Covar, R | 1 |
| Holguin, F | 1 |
| Lemanske, RF | 1 |
| Martinez, FD | 1 |
| Pongracic, JA | 2 |
| Beigelman, A | 1 |
| Baxi, SN | 1 |
| Benson, M | 1 |
| Blake, K | 1 |
| Chmiel, JF | 2 |
| Daines, CL | 1 |
| Daines, MO | 1 |
| Gaffin, JM | 1 |
| Gentile, DA | 1 |
| Gower, WA | 1 |
| Israel, E | 1 |
| Kumar, HV | 1 |
| Lang, JE | 1 |
| Lazarus, SC | 1 |
| Lima, JJ | 1 |
| Ly, N | 1 |
| Marbin, J | 1 |
| Morgan, W | 1 |
| Myers, RE | 1 |
| Olin, JT | 1 |
| Peters, SP | 1 |
| Raissy, HH | 1 |
| Robison, RG | 1 |
| Ross, K | 1 |
| Sorkness, CA | 2 |
| Thyne, SM | 1 |
| Szefler, SJ | 2 |
| Earnshaw, SR | 1 |
| Wilson, MR | 1 |
| Dalal, AA | 1 |
| Chambers, MG | 1 |
| Jhingran, P | 1 |
| Stanford, R | 1 |
| Mapel, DW | 1 |
| Anzueto, A | 1 |
| Ferguson, GT | 1 |
| Feldman, G | 1 |
| Chinsky, K | 1 |
| Seibert, A | 1 |
| Emmett, A | 1 |
| Knobil, K | 1 |
| O'Dell, D | 1 |
| Kalberg, C | 1 |
| Crater, G | 1 |
| Cross, KP | 1 |
| Randell, KA | 1 |
| Herr, SM | 1 |
| Doan, Q | 1 |
| Shefrin, A | 1 |
| Johnson, D | 1 |
| Wildfire, JJ | 1 |
| Gergen, PJ | 1 |
| Mitchell, HE | 1 |
| Calatroni, A | 1 |
| Kattan, M | 1 |
| Teach, SJ | 1 |
| Bloomberg, GR | 1 |
| Wood, RA | 1 |
| Liu, AH | 1 |
| Conroy, K | 1 |
| Rivera-Sanchez, Y | 1 |
| Busse, WW | 1 |
| Morgan, WJ | 1 |
| Venditti, F | 1 |
| Bellandi, B | 1 |
| Parodi, G | 1 |
| Hofhuis, W | 1 |
| van der Wiel, EC | 1 |
| Tiddens, HA | 1 |
| Brinkhorst, G | 1 |
| Holland, WP | 1 |
| de Jongste, JC | 1 |
| Merkus, PJ | 1 |
| Teper, AM | 1 |
| Colom, AJ | 1 |
| Kofman, CD | 1 |
| Maffey, AF | 1 |
| Vidaurreta, SM | 1 |
| Bergadá, I | 1 |
| Chandra, P | 1 |
| Paliwal, L | 1 |
| Lodha, R | 1 |
| Kabra, SK | 1 |
| Salpeter, SR | 1 |
| Buckley, NS | 1 |
| Ormiston, TM | 1 |
| Salpeter, EE | 1 |
| Holt, EW | 1 |
| Tan, J | 1 |
| Hosgood, HD | 1 |
| Perera, WR | 1 |
| Hurst, JR | 1 |
| Wilkinson, TM | 1 |
| Sapsford, RJ | 1 |
| Müllerova, H | 1 |
| Donaldson, GC | 1 |
| Wedzicha, JA | 1 |
| Rowe, BH | 1 |
| Wong, E | 1 |
| Blitz, S | 1 |
| Diner, B | 1 |
| Mackey, D | 1 |
| Ross, S | 1 |
| Senthilselvan, A | 1 |
| Galoppin, L | 1 |
| de Blic, J | 1 |
| Azevedo, I | 1 |
| Scheinmann, P | 1 |
| Vargaftig, BB | 1 |
| Bachelet, M | 1 |
| Lyttle, BD | 1 |
| Hollestelle, AM | 1 |
| Lenney, W | 1 |
| Pedersen, S | 1 |
| Boner, AL | 1 |
| Ebbutt, A | 1 |
| Jenkins, MM | 1 |
| Klig, JE | 1 |
| Hodge, D | 1 |
| Rutherford, MW | 1 |
| Baker, EK | 1 |
| Willsie, SK | 1 |
| Marinac, JS | 1 |
| Salzman, GA | 1 |
| Hayden, MJ | 1 |
| Wildhaber, JH | 1 |
| LeSouëf, PN | 1 |
| Chang, AB | 1 |
| Phelan, PD | 1 |
| Carlin, JB | 1 |
| Sawyer, SM | 1 |
| Robertson, CF | 1 |
| Derksen, FJ | 1 |
| Olszewski, MA | 1 |
| Robinson, NE | 1 |
| Berney, C | 1 |
| Hakala, JE | 2 |
| Matson, CJ | 2 |
| Ruth, DT | 1 |
| Rush, BR | 2 |
| Hoskinson, JJ | 1 |
| Davis, EG | 1 |
| Ploin, D | 1 |
| Chapuis, FR | 1 |
| Stamm, D | 1 |
| Robert, J | 1 |
| David, L | 1 |
| Chatelain, PG | 1 |
| Dutau, G | 1 |
| Floret, D | 1 |
| Duane, M | 1 |
| Chandran, L | 1 |
| Morelli, PJ | 1 |
| Henrikson, SL | 1 |
| Gromova, OA | 1 |
| Gusel', VA | 1 |
| Frans, A | 1 |
| Prasher, VP | 1 |
| Corbett, JA | 1 |
| Sheehan, GJ | 1 |
| Kutzner, MR | 1 |
| Chin, WD | 1 |
| Prendiville, A | 1 |
| Rose, A | 1 |
| Maxwell, DL | 1 |
| Silverman, M | 1 |
| Carson, JW | 1 |
| Taylor, MR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MN-221-CL-007: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma[NCT00838591] | Phase 2 | 176 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Modification of Disease Outcome in COPD. Shortterm Versus Longterm Treatment With Inhaled Corticosteroids, Either or Not Combined With a Long-Acting Beta2-Agonist.[NCT00158847] | Phase 4 | 200 participants | Interventional | 2000-04-30 | Terminated | ||
| Individualized Therapy For Asthma in Toddlers[NCT01606306] | Phase 3 | 300 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| A Randomized Trial Comparing Metered Dose Inhalers and Breath Actuated Nebulizers[NCT02777125] | 980 participants (Actual) | Interventional | 2014-10-31 | Completed | |||
| Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of ORal Bacterial EXtract for the Prevention of Wheezing Lower Respiratory Tract Illness (ORBEX)[NCT02148796] | Phase 2 | 822 participants (Actual) | Interventional | 2017-01-03 | Active, not recruiting | ||
| Oral Dexamethasone Versus Oral Prednisone in Children Hospitalized With Asthma: A Randomized Control Study[NCT02780479] | Phase 4 | 6 participants (Actual) | Interventional | 2017-03-20 | Terminated (stopped due to insufficient number of participants met the enrollment criteria.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome was differential response to the three therapies on the basis of fixed threshold criteria for the following asthma control measures, which encompassed domains of risk and impairment: the time from the start of the treatment period to an asthma exacerbation treated with systemic corticosteroids, and the annualized number of asthma control days (ACDs) from within that period. ACDs were defined as full calendar days without symptoms, rescue medication use, or unscheduled healthcare visits. Children were defined as differential responders if, first, the time to an asthma exacerbation was at least four weeks longer, or second, if the number of annualized ACDs was at least 31 days more for one treatment than another, in that order. If neither threshold was met, the participant was considered a non differential responder. Differential response was determined in children completing at least two treatment periods and at least 50% of the daily diary entries for each period. (NCT01606306)
Timeframe: The last 14 weeks of each 16-week treatment period
| Intervention | probability (Number) | |||
|---|---|---|---|---|
| Non-differential responders | Responded best to daily ICS | Responded best to daily LTRA | Responded best to as-needed ICS | |
| All Evaluable Participants | .26 | .40 | .18 | .16 |
Patient disposition is measured as subjects requiring further treatment and being admitted to hospital. We record the number of patients in each cohort that required admission to the hospital after being evaluated and treated in the Emergency Department. (NCT02777125)
Timeframe: 6 hours
| Intervention | Participants admitted to the Hospital (Number) |
|---|---|
| Albuterol by Metered Dose Inhaler | 53 |
| Albuterol Breath Actuated Nebulizer | 57 |
Defined as a repeat visit to the Emergency Department for a complaint related to their wheezing, within 7 days of initial enrollment in the study. (NCT02777125)
Timeframe: Within 7 days of initial presentation
| Intervention | Participants (Count of Participants) |
|---|---|
| Albuterol by Metered Dose Inhaler | 5 |
| Albuterol Breath Actuated Nebulizer | 4 |
Defined as a patient needing ondansetron for symptomatic relief of their nausea after initiating therapy in the Emergency Department. (NCT02777125)
Timeframe: 6 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Albuterol by Metered Dose Inhaler | 14 |
| Albuterol Breath Actuated Nebulizer | 18 |
Defined as anytime after initiation of therapy when the patient's heart rate exceeded age adjusted normal sinus rhythm heart rates for their age. Not uncommonly, patient's experience tachycardia as an unintended side effect of receiving albuterol. Tachycardia can result in a patient requiring further observation in the Emergency department and therefore increasing Emergency Department length of stay. We want to determine if indeed tachycardia is unavoidable, or if its presence suggests that patients are receiving too much albuterol or if albuterol is being given by the wrong appliance. (NCT02777125)
Timeframe: 6 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Albuterol by Metered Dose Inhaler | 101 |
| Albuterol Breath Actuated Nebulizer | 141 |
Emergency department length of stay is defined as the point of time when the patient checked into the Emergency Department to the time of final disposition. (NCT02777125)
Timeframe: 6 hours
| Intervention | minutes (Mean) | |
|---|---|---|
| Mild severity | Moderate severity | |
| Albuterol Breath Actuated Nebulizer | 197 | 245 |
| Albuterol by Metered Dose Inhaler | 192 | 232 |
2 reviews available for albuterol and Recrudescence
| Article | Year |
|---|---|
Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Ch | 2006 |
Efficacy and safety of salmeterol in childhood asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Analysis of Variance; A | 1995 |
13 trials available for albuterol and Recrudescence
| Article | Year |
|---|---|
Repeated dyspnea score and percent FEV1 are modest predictors of hospitalization/relapse in patients with acute asthma exacerbation.
Topics: Acute Disease; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; | 2014 |
Relapse in FEV1 Decline After Steroid Withdrawal in COPD.
Topics: Administration, Inhalation; Aged; Albuterol; Androstadienes; Bronchodilator Agents; Cohort Studies; | 2015 |
Individualized therapy for persistent asthma in young children.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Asthma; Child, Preschool; Female; Fo | 2016 |
Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes.
Topics: Administration, Inhalation; Aged; Albuterol; Androstadienes; Bronchodilator Agents; Dose-Response Re | 2009 |
Development and validation of the Composite Asthma Severity Index--an outcome measure for use in children and adolescents.
Topics: Adolescent; Adult; Albuterol; Algorithms; Asthma; Disease Progression; Drug Utilization; Female; Fol | 2012 |
Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Bone and Bones; Bronchodilator Agents | 2004 |
Comparison of terbutaline and salbutamol inhalation in children with mild or moderate acute exacerbation of asthma.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Confidence Intervals; Dose-Respons | 2004 |
Adding long-acting beta-agonists to inhaled corticosteroids after discharge from the emergency department for acute asthma: a randomized controlled trial.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adrenergic be | 2007 |
Efficacy and safety of salmeterol in childhood asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Analysis of Variance; A | 1995 |
Symptomatic improvement following emergency department management of asthma: a pilot study of intramuscular dexamethasone versus oral prednisone.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Age Factors; Albuterol; Anti-Inflammat | 1997 |
A randomised, placebo controlled trial of inhaled salbutamol and beclomethasone for recurrent cough.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Beclomethasone; Bronchi | 1998 |
High-dose albuterol by metered-dose inhaler plus a spacer device versus nebulization in preschool children with recurrent wheezing: A double-blind, randomized equivalence trial.
Topics: Acute Disease; Albuterol; Bronchodilator Agents; Child, Preschool; Dose-Response Relationship, Drug; | 2000 |
Efficacy of salmeterol xinafoate in horses with recurrent airway obstruction.
Topics: Administration, Inhalation; Airway Obstruction; Albuterol; Animals; Bronchodilator Agents; Cross-Ove | 2001 |
25 other studies available for albuterol and Recrudescence
| Article | Year |
|---|---|
Severe hypokalemia secondary to abuse of β-adrenergic agonists in a pediatric patient: Case report.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Drug Overdose; Factitious Disorders; Humans; Hypoka | 2019 |
Hyperkalemia in children with nephrotic syndrome.
Topics: Administration, Inhalation; Albuterol; Biomarkers; Child; Child, Preschool; Combined Modality Therap | 2013 |
Idiopathic stuttering priapism treated with salbutamol orally: a case report.
Topics: Administration, Oral; Adrenergic beta-2 Receptor Agonists; Albuterol; Androgen Antagonists; Azoosper | 2016 |
Tidal changes in respiratory resistance are sensitive indicators of airway obstruction in children.
Topics: Airway Resistance; Albuterol; Anthropometry; Asthma; Bronchodilator Agents; Child; Child, Preschool; | 2016 |
Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
Topics: Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Anti-Asthmatic Agents; Cost-Benefit Analy | 2009 |
A 19-month-old boy with recurrent respiratory distress.
Topics: Acid-Base Equilibrium; Albuterol; Alkalosis, Respiratory; Aspirin; Asthma; Bicarbonates; Bites, Huma | 2010 |
Cost-effectiveness of metered-dose inhalers for asthma exacerbations in the pediatric emergency department.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; British Columbia; Child; Child, Preschool | 2011 |
Fatal Tako-Tsubo cardiomyopathy recurrence after β2-agonist administration.
Topics: Adrenergic beta-2 Receptor Agonists; Aged, 80 and over; Albuterol; Fatal Outcome; Female; Humans; Re | 2012 |
Bronchodilation in infants with malacia or recurrent wheeze.
Topics: Administration, Oral; Adrenergic beta-Agonists; Albuterol; Bronchial Diseases; Bronchodilator Agents | 2003 |
Summaries for patients. What are the risks of using inhaled long-acting beta-agonist medications for the relief of asthma?
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Ch | 2006 |
The impact of spirometry on pediatric asthma diagnosis and treatment.
Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Adolescent; Albuterol; Anti-Inflamm | 2006 |
Inflammatory changes, recovery and recurrence at COPD exacerbation.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aged; Albuterol; Biomarkers; C-Reactive Protei | 2007 |
Nonspecific refractoriness to adenylyl cyclase stimulation in alveolar macrophages from infants with recurrent bronchiolitis.
Topics: Adenylyl Cyclases; Albuterol; Asthma; Bronchiolitis; Bronchoalveolar Lavage Fluid; Bronchoscopy; Col | 1994 |
Asthma. Assessment and management in a pediatric hospital.
Topics: Acute Disease; Albuterol; Asthma; Canada; Child; Child, Preschool; Emergency Medicine; Emergency Ser | 1993 |
Continuously nebulized albuterol in severe exacerbations of asthma in adults: a case-controlled study.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Arrhythmia | 1997 |
Bronchodilator responsiveness testing using raised volume forced expiration in recurrently wheezing infants.
Topics: Albuterol; Bronchi; Bronchodilator Agents; Child; Female; Forced Expiratory Flow Rates; Humans; Lung | 1998 |
Aerosolized albuterol sulfate used as a bronchodilator in horses with recurrent airway obstruction.
Topics: Administration, Inhalation; Aerosols; Airway Obstruction; Albuterol; Animals; Bronchodilator Agents; | 1999 |
Pulmonary distribution of aerosolized technetium Tc 99m pentetate after administration of a single dose of aerosolized albuterol sulfate in horses with recurrent airway obstruction.
Topics: Administration, Inhalation; Aerosols; Airway Obstruction; Albuterol; Animals; Bronchodilator Agents; | 1999 |
Recurrent supraventricular tachycardia as a complication of nebulized albuterol treatment.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Electrocardiography; He | 2000 |
[Study of circadian rhythm of bronchial patency for timely correction and evaluation of the effectiveness of inhalation powder forms of salbutamol in children with bronchial asthma].
Topics: Administration, Inhalation; Adolescent; Airway Obstruction; Albuterol; Asthma; Bronchi; Child; Circa | 1992 |
[Abolition of the salbutamol-induced bronchodilating effect during bronchial infection in patients with chronic obstructive bronchopulmonary diseases].
Topics: Albuterol; Chronic Disease; Humans; Lung Diseases, Obstructive; Middle Aged; Recurrence | 1992 |
Aerosol addiction.
Topics: Adult; Aerosols; Albuterol; Asthma; Humans; Intellectual Disability; Male; Nebulizers and Vaporizers | 1990 |
Acute asthma attack due to ophthalmic indomethacin.
Topics: Aged; Albuterol; Asthma; Combined Modality Therapy; Female; Glucocorticoids; Humans; Indomethacin; O | 1989 |
Hypoxaemia in wheezy infants after bronchodilator treatment.
Topics: Albuterol; Carbon Dioxide; Humans; Hypoxia; Infant; Oxygen; Partial Pressure; Recurrence; Respirator | 1987 |
Relapse after single dose nebulised salbutamol in children with acute asthma.
Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Female; Humans; Male; Peak Expiratory Flow R | 1985 |